Investor Presentation

RNS Number : 6434V

Advanced Oncotherapy PLC

30 October 2014

 



30 October 2014

ADVANCED ONCOTHERAPY Plc

("Advanced Oncotherapy" or the "Company")

Investor presentation

Advanced Oncotherapy (AIM: AVO), the developer of next generation proton therapy systems for cancer treatment,announces that it will be hosting an investor and analyst presentation on Tuesday 18 November 2014. The briefing will outline Advanced Oncotherapy's strategy and key milestones for the development and commercialisation of its proton therapy system: LIGHT (Linac for Image Guided Hadron Therapy).

The event will be held at the Royal Society of Medicine (1 Wimpole St, London W1G 0AE) with presentations beginning at 4pm, and will be followed by drinks and canapés at 5.30pm. The timetable for the event is as follows:

15:45	Doors open
16:00	Overview of Advanced Oncotherapy Sanjeev Pandya, CEO
16:15 16:30	From CERN to the patient Steve Myers, Head of the Office of Medical Applications at CERN and former CERN's Director of Accelerators and Technology Overview of the LIGHT accelerator Donatella Ungaro, Managing Director of ADAM
16.40	LIGHT - A medical physicist perspective Professor  Hanne Kooy, Department of Radiation Oncology of Harvard Medical School & Chairman of AVO's Product Development Committee
16.55	Corporate milestones for a newly focussed business Sanjeev Pandya, CEO & Nicholas Serandour, CFO
17.10	Q&As
17.30	Drinks & canapés

To register to attend the event, or to receive further information on Advanced Oncotherapy, please contact Walbrook PR on 020 7933 8780 or email [e-mail].

For further information contact:

Advanced Oncotherapy Plc	www.avoplc.com
Sanjeev Pandya, CEO	Tel: [phone]
Nicholas Serandour, CFO	Tel: [phone]
Westhouse Securities (Nomad & Joint Broker)	Tel: [phone]
Antonio Bossi / David Coaten
Beaufort Securities (Joint Broker)	Tel: [phone]
Saif Janjua / Jon Levinson
Walbrook PR (Financial PR & IR)	Tel: [phone] or [e-mail]
Paul McManus / Anna Dunphy	Mob: [phone] / Mob: [phone]

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy's team based at CERN in Geneva focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. As a result, Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

 

END

 

 

NRAUKONRSBARUAA